Impax Labs Appoints Frederick Wilkinson As President And CEO - Quick Facts

(RTTNews) - Impax Laboratories Inc.(IPXL) said Monday that it appointed Frederick Wilkinson as its President and Chief Executive Officer effective April 29, 2014. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis plc succeeds Larry Hsu, who is retiring.

Wilkinson, 57, joined Watson Pharmaceuticals Inc. (now Actavis) as Executive Vice President, Global Brands in September 2009. Before joining to Watson, he was President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of Barr Pharmaceuticals Inc. from 2006 to 2009. Prior to joining Duramed Pharmaceuticals, Inc., he was President and Chief Executive Officer of Columbia Laboratories, Inc. from 2001 to 2006. From 1996 to 2001, Wilkinson was Senior Vice President and Chief Operating Officer of Watson. Prior to joining Watson, he spent 16 years at Sandoz in numerous senior management positions of increasing responsibility.

Today's announcement concludes a transition process that began in 2013 when Hsu first announced his decision to retire. Hsu will continue to serve on the Impax Board, the company said.

The company stated that it will release its first quarter 2014 financial results after the close of the U.S. financial markets on May 1, 2014.